BioNTech Shares Gain Momentum from Regulatory and Analyst Support
Published on 09/23/2025 at 11:45 | Redaktion boerse-global.de
After an extended period of decline, BioNTech stock is showing signs of a potential recovery. Investor sentiment received a dual boost on Monday, raising questions about whether this momentum is sufficient to lift the German vaccine developer from its prolonged slump.
The positive developments stem from both Wall Street and a key US health committee. In a significant move, JPMorgan analyst Jessica Fye increased her price target for BioNTech to $121 from $116, representing an uplift of more than 4%. This adjustment was attributed to a recent update of the company’s financial model. This vote of confidence follows other optimistic analyst appraisals, including a reiterated ‘Buy’ rating from HC Wainwright & Co. in early September, which came with a $136 price objective.
Simultaneously,... Read more...
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
